[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648092":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":10,"responsibleParty":26,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":32,"acronym":33,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":10,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":44,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"French Cardiology Society","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patient with a diagnosis of HCM with significant obstruction",null,"Patient with a diagnosis of HCM with significant obstruction (left intraventricular gradient at rest or during Valsalva maneuver ≥ 50 mmHg) and symptomatic (NYHA class 2 or 3) and started treatment with Mavacamten",[13],{"name":14,"affiliation":15,"role":16},"Morgane HERRY","Hopital Lariboisière","PRINCIPAL_INVESTIGATOR",[18,24],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"Dr Morgane HERRY, MD","CONTACT","01 44 90 70 28","+33","impact@sfcardio.fr",{"name":25,"role":20,"phone":21,"phoneExt":22,"email":23},"Pr Damien LOGEART, MD",{"type":27,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100648092","impact-cmh-impact-of-mitral-valve-and-subvalvular-abnormalities-in-obstructive-hypertrophic-cardiomyopathy-treated-with-mavacamten-100648092",false,"NCT07716826","IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten","IMPACT-CMH","Inclusion Criteria:\n\n* Inclusion Criteria :\n* Age ≥18 years\n* Patients who are informed and consent to participate\n* CMH with significant obstruction (left intraventricular gradient at rest or during Valsalva maneuver ≥ 50 mmHg) and symptomatic (NYHA class 2 or 3)\n* Patients who have started treatment with Mavacamten\n\nExclusion Criteria:\n\n* Patients who refuse to participate in this register","ALL","18 Years",{"count":38,"type":39},150,"ESTIMATED","OBSERVATIONAL","The objective of this observational study is to evaluate the association between the presence of mitral valvular and\u002For subvalvular anatomical abnormalities prior to initiation of mavacamten and the hemodynamic response at 6 months in patients with obstructive HCM treated with mavacamten. The secondary objective is to determine the impact of different types of anatomical abnormalities of the mitral valve and subvalvular structures on the hemodynamic and clinical response to mavacamten.",[43],"Cardiomyopathy, Hypertrophic Obstructive",[43,45,46,47],"mavacamten","mitral valve","subvalvular structures","NOT_YET_RECRUITING","2026-07-16",{"date":51,"type":52},"2026-07-21","ACTUAL",{"date":54,"type":39},"2026-09",{"date":56,"type":39},"2026-12",{"name":5,"class":6}]